StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of GLMD opened at $9.35 on Monday. Galmed Pharmaceuticals has a twelve month low of $2.73 and a twelve month high of $23.80. The company has a market capitalization of $47.17 million, a P/E ratio of -3.90 and a beta of 0.67. The firm has a 50 day moving average of $4.22 and a 200 day moving average of $4.23.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- The Average 401k Balance by Age Explained
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- How to buy stock: A step-by-step guide for beginners
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
